Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 370

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 370
---
 coverage is achieved at 40X, whereas LPG covers the genome at 0.5 -1X. The resulting sequencing data (FASTQ) is analyzed with our imputation and analysis platform in AWS to obtain a variant file (VCF) with more than 99% accuracy of genome -widevariants. LPG returns more data and statistical power than microarray technology, making it the reference technology for high -throughputgenomics applications. We employ a genomic imputation pipeline that processes low -coveragewhole genome sequencing data (0.5 - 1Xcoverage) using the GLIMPSE software framework ( https://www.nature.com/articles/s41588 -020-00756-0). The pipeline operates on a high -performancecomputing infrastructure utilizing GRCh37 as the reference genome, with data processing orchestrated through the Nextflow workflow management system. Raw sequencing data undergoes quality control before being aligned to the reference genome, followed by genotype imputation using the 1000 Genomes Phase 3 reference panels. Regarding risks associated with the compilation of the PRS scores, the main risk to mention is the ancestry genetic background, which may or may not modify the PRS utility for a given local population. This risk assessed through our validation protocols with local populations. Additional risks include potential inaccuracies due to the limitations of imputation -basedgenotype predictions, the evolving nature of polygenic risk research, and the possibility of overestimating or underestimating disease risk in individuals. Moreover, environmental and lifestyle factors, which PRS alone cannot account for, also play a significant role in disease development, underscoring the importance of a holistic approach when interpreting PRS results. At present, we have compiled PRS for breast cancer, prostate cancer, coronary artery diseases (CAD), and type II diabetes. In Argentina, we offer Rewell as a business -to - business-to -consumerservice, commercialized through select laboratories and partners. Customers purchase a “Complete Profile Kit,” which includes materials and instruction for collecting saliva and stool samples. Once their samples are collected, samples are transported for processing to our Argentine Wet -Lab, which we lease from CIBIC. Once processed, customers can view their DNA and gut microbiome test results either on our secure and proprietary digital platform or as a report. The results are processed using our bioinformatics pipeline, which incorporates our proprietary machine learning models and integrates them with our standard and proprietary databases. Results are categorized into sections such as nutrition, ancestry, health and prevention,